

## Contents

<b>Chapter 1</b>	
General introduction and rationale for this thesis	9
<b>Chapter 2</b>	
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial <i>Diabetes Care 2009;32:762-768</i>	35
<b>Chapter 3</b>	
One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress <i>Atherosclerosis 2010;212:223-229</i>	53
<b>Chapter 4</b>	
One-year exenatide and insulin glargine treatment improves prandial beta-cell response in metformin treated patients with type 2 diabetes <i>Diabetes Obes Metab (Submitted for publication)</i>	75
<b>Chapter 5</b>	
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition <i>Diabetes Care 2010;33:1734-1737</i>	95
<b>Chapter 6</b>	
Effects of exenatide on measures of beta-cell function after 3-years in metformin-treated patients with type 2 diabetes <i>Diabetes Care (Accepted for publication)</i>	107
<b>Chapter 7</b>	
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes <i>Diabetes Obes Metab 2011;13:374-377</i>	125
<b>Chapter 8</b>	
Incretin mimetics as a novel therapeutic option for hepatic steatosis <i>Liver Int 2006;26:1015-1017</i>	133

**Chapter 9**

Summary and conclusion 139

**Chapter 10**

Samenvatting voor de geïnteresseerde leek 166

List of abbreviations 174

Affiliation of co-authors 176

List of publications 178

Dankwoord/Acknowledgments 181

Curriculum vitae 185